405,576 Shares in Arvinas, Inc. (NASDAQ:ARVN) Purchased by Baker BROS. Advisors LP

Baker BROS. Advisors LP purchased a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 405,576 shares of the company's stock, valued at approximately $9,989,000. Baker BROS. Advisors LP owned approximately 0.59% of Arvinas as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in Arvinas in the second quarter valued at $42,000. nVerses Capital LLC bought a new stake in Arvinas in the third quarter valued at $39,000. Amalgamated Bank boosted its holdings in Arvinas by 29.6% in the second quarter. Amalgamated Bank now owns 2,223 shares of the company's stock valued at $59,000 after acquiring an additional 508 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock valued at $61,000 after buying an additional 440 shares in the last quarter. Finally, Quantbot Technologies LP grew its position in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after buying an additional 2,601 shares during the period. Institutional investors own 95.19% of the company's stock.

Arvinas Stock Performance

ARVN traded down $1.00 on Monday, hitting $25.72. The company had a trading volume of 534,434 shares, compared to its average volume of 713,529. The stock has a fifty day moving average price of $25.68 and a 200-day moving average price of $26.70. Arvinas, Inc. has a 12-month low of $21.17 and a 12-month high of $53.08. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -5.72 and a beta of 1.96.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.20. The company had revenue of $102.40 million during the quarter, compared to analysts' expectations of $60.56 million. Arvinas's revenue for the quarter was up 196.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.18) EPS. Analysts forecast that Arvinas, Inc. will post -3.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ARVN. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a research report on Monday, September 9th. Stephens began coverage on shares of Arvinas in a research report on Monday, November 18th. They issued an "overweight" rating and a $55.00 target price on the stock. BMO Capital Markets reduced their target price on shares of Arvinas from $90.00 to $88.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 20th. Oppenheimer reduced their target price on shares of Arvinas from $50.00 to $40.00 and set an "outperform" rating on the stock in a research report on Thursday, October 31st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $87.00 target price on shares of Arvinas in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Arvinas has an average rating of "Moderate Buy" and a consensus price target of $61.08.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.